[Piperacillin/tazobactam--Tazocin. A penicillin-based alternative to 3rd generation cephalosporins and carbapenems].
The antibiotic piperacillin/tazobactam has recently been licensed for use in Denmark. Piperacillin/tazobactam combines a well known beta-lactam antibiotitic, piperacillin, and an inhibitor of bacterial beta-lactamase, tazobactam. The combination of piperacillin and tazobactam compared to piperacillin alone has an expanded antimicrobial spectrum, which includes Klebsiellae, Escherichia coli, and Proteus vulgaris resistant to ampicillin, as well as beta-lactamase-producing Staphylococcus aureus. As piperacillin in itself possesses antimicrobial activity against streptococci, enterococci, and Pseudomonas aeruginosa, the antimicrobial activity of piperacillin/tazobactam indicates that the combination may constitute an alternative to third generation cephalosporins and carbapenems in the treatment of complicated intra-abdominal infections infections in critically ill patients and for the empirical treatment of acute neutropenic febrile patients, as indicated by clinical studies.
Schønning
Kristian
K
Klinisk mikrobiologisk afdeling, H:S Rigshospitalet, DK-2100 København.
Tvede
Michael
M
D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D005767:Gastrointestinal Diseases / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D010406:Penicillins / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D010878:Piperacillin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D010406:Penicillins; D010878:Piperacillin
Piperacillin/tazobactam--Tazocin. Et penicillinbaseret alternativ til 3.-generations cefalosporiner og carbapenemer.